Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial design with a safety run-in period will be used to assess the
rate of VGPR or better for the combination PVD-Dara in the treatment of RRMM.